RegulatoryAmgen’s Biosimilar of AstraZeneca’s Rare Blood Condition Therapy Gets...

Amgen’s Biosimilar of AstraZeneca’s Rare Blood Condition Therapy Gets Approved by the US FDA

-

The U.S. Food and Drug Administration has approved Bkemv by Amgen, the first biosimilar to AstraZeneca’s Soliris, used to treat a rare blood condition. Known as Bkemv in the pharmaceutical market, this medicine represents a significant advancement in providing alternatives to complex biological preparations. While its approval has positive aspects, it also includes a black box warning about the potential for severe infection caused by Neisseria meningitidis bacteria.

Research showed that Amgen’s journey to approval saw the success of Bkemv in a late-stage study conducted in 2022, where it demonstrated comparable safety and immunogenicity to Soliris. This accomplishment is even more impressive considering AstraZeneca’s significant investment in acquiring Soliris as part of its $39 billion purchase of Alexion Pharmaceuticals in 2020.

Bkemv’s approval extends to treating two rare blood disorders: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. These conditions, resulting from immune system disturbances, destroy red blood cells and platelets, potentially leading to anemia and kidney failure.

The FDA’s decision to categorize Bkemv as an interchangeable biosimilar to Soliris means that the two products are very similar, with no clinically significant differences. This classification is beneficial for informing healthcare providers and patients about this medication’s effectiveness and safety profile.

The FDA’s approval of Amgen’s Bkemv as a biosimilar to AstraZeneca’s Soliris is a major step forward in ensuring that eligible patients with these disorders have the best treatment options. This decision underscores the importance of continued advancements in the development of biopharmaceuticals that can improve disease treatment while maintaining stringent measures to protect patients’ lives from risky treatments.

Latest news

BioNTech Agrees to $205 Million FDA Voucher Purchase for Oncology Pipeline

BioNTech has agreed to pay $205 million to acquire an FDA priority review voucher (PRV) from Scholar Rock, securing...

The Science Behind Bispecific Antibodies and Their Therapeutic Potential

Executive Summary Bispecific antibodies are an increasingly important class of engineered biologic medicines designed to recognize two distinct molecular targets...

Top 10 Emerging Technologies in Microbial Biotechnology

Executive Summary Microbial biotechnology is advancing as new technologies expand the ability to engineer, understand, and utilize microorganisms for industrial,...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you